|
1
|
Kanjanapan Y, Day D, Butler MO, Wang L,
Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, et
al: Delayed immune-related adverse events in assessment for
dose-limiting toxicity in early phase immunotherapy trials. Eur J
Cancer. 107:1–7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tang SQ, Tang LL, Mao YP, Li WF, Chen L,
Zhang Y, Guo Y, Liu Q, Sun Y, Xu C and Ma J: The pattern of time to
onset and resolution of immune-related adverse events caused by
immune checkpoint inhibitors in cancer: A pooled analysis of 23
clinical trials and 8,436 patients. Cancer Res Treat. 53:339–354.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sun L, Bleiberg B, Hwang WT, Marmarelis
ME, Langer CJ, Singh A, Cohen RB, Mamtani R and Aggarwal C:
Association between duration of immunotherapy and overall survival
in advanced non-small cell lung cancer. JAMA Oncol. 9:1075–1082.
2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Morad G, Helmink BA, Sharma P and Wargo
JA: Hallmarks of response, resistance, and toxicity to immune
checkpoint blockade. Cell. 184:5309–5337. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baden MY, Imagawa A, Abiru N, Awata T,
Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, et
al: Characteristics and clinical course of type 1 diabetes mellitus
related to anti-programmed cell death-1 therapy. Diabetol Int.
10:58–66. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Le Burel S, Champiat S, Mateus C,
Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S,
Voisin AL, et al: Prevalence of immune-related systemic adverse
events in patients treated with anti-Programmed cell Death
1/anti-Programmed cell Death-Ligand 1 agents: A single-centre
pharmacovigilance database analysis. Eur J Cancer. 82:34–44.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kostine M, Rouxel L, Barnetche T, Veillon
R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S,
Beylot-Barry M, et al: Rheumatic disorders associated with immune
checkpoint inhibitors in patients with cancer-clinical aspects and
relationship with tumour response: A single-centre prospective
cohort study. Ann Rheum Dis. 77:393–398. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kita T, Araya T, Sakai T, Uchida Y,
Matsuoka H and Kasahara K: Nivolumab-Induced polymyalgia rheumatica
in a patient with lung adenocarcinoma. Am J Med Sci. 362:321–323.
2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Vermeulen OCB, Brouwer E, Slart RHJA,
Sandovici M, Rutgers A, Hilterman TJ, Hiddinga B, Oosting SF,
Jalving M, de Heij AH, et al: Immune checkpoint inhibitor-mediated
polymyalgia rheumatica versus primary polymyalgia rheumatica:
Comparison of disease characteristics and treatment requirement.
Rheumatology (Oxford). 64:771–779. 2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Waterhouse DM, Garon EB, Chandler J,
McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan
B, et al: Continuous versus 1-year fixed-duration nivolumab in
previously treated advanced non-small-cell lung cancer: CheckMate
153. J Clin Oncol. 38:3863–3873. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ardin C, Humez S, Leroy V, Ampere A,
Bordier S, Escande F, Turlotte A, Stoven L, Nunes D, Cortot A and
Gauvain C: Pursuit or discontinuation of anti-PD1 after 2 years of
treatment in long-term responder patients with non-small cell lung
cancer. Ther Adv Med Oncol. 15(17588359231195600)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Couey MA, Bell RB, Patel AA, Romba MC,
Crittenden MR, Curti BD, Urba WJ and Leidner RS: Delayed
immune-related events (DIRE) after discontinuation of
immunotherapy: Diagnostic hazard of autoimmunity at a distance. J
Immunother Cancer. 7(165)2019.PubMed/NCBI View Article : Google Scholar
|
